Cardiol Therapeutics Inc.
No SEC Form 4 filings for $CRDL in the last 30 days.
See all $CRDL insider activity →Cardiol Therapeutics (CRDL) raised over $7M from warrant exercises, extending its cash runway to H1 2028. The funds will support its Phase III MAVERIC trial for recurrent pericarditis and regulatory preparations for CardiolRx™, its lead drug candidate.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) filed a US$150 million preliminary base shelf prospectus, allowing potential future offerings. The filing includes expanded program and expense disclosure following OSC staff review. The company is advancing CardiolRx™ for heart disease treatments and developing CRD-38 for inflammatory heart disease.
Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CRDL (Cardiol Therapeutics Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CRDL coverage spans financial news, market movers and corporate actions.
Modest capital infusion improves liquidity but is small relative to typical biotech financing.
The filing signals potential future capital raising but does not commit to an immediate issuance.
Positive trial advancement may boost near‑term price.
Loss improvement may improve sentiment but limited upside.
Orphan‑drug status could drive future valuation; short‑term risk limited.
AlphAI scores every news story that mentions CRDL with an AI model for sentiment and relevance, and aggregates insider trades from Cardiol Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cardiol Therapeutics (CRDL) raised over $7M from warrant exercises, extending its cash runway to H1 2028. The funds will support its Phase III MAVERIC trial for recurrent pericarditis and regulatory preparations for CardiolRx™, its lead drug candidate.
2 min readCardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) filed a US$150 million preliminary base shelf prospectus, allowing potential future offerings. The filing includes expanded program and expense disclosure following OSC staff review. The company is advancing CardiolRx™ for heart disease treatments and developing CRD-38 for inflammatory heart disease.
2 min readFive biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
3 min readSummit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
3 min readSeveral biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
3 min readAndrew Peller (ADW.A) reached a 52-week high of $8.00 after completing a transaction with Fairfax. Algoma Central (ALC.TO) hit $25.25, reporting Q2 revenues of $258,273. Argo Graphene (C.ARGO) hit $1.15 after appointing a new CEO. Boralex (BLX) reached $37.24 following its acquisition by Brookfield. Bank of Montreal (BMO) hit $258.11 after selling Moneris. Other companies also hit 52-week highs with varying news.
3 min readThe article compares small-cap medical stocks Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL). It cites beta values of 0.3 for APM and 0.77 for CRDL, institutional ownership of 3.8% vs 12.5%, and insider ownership of 64.0% vs 5.3%. MarketBeat data shows CRDL consensus target price of $8.50 (upside 553.85%). It also states APM has higher revenue and earnings.
4 min readCardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the company. The company also provided updates on its clinical trials for CardiolRx™ in recurrent pericarditis and acute myocarditis, and the development of CRD-38 for heart failure.
4 min readInnovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
4 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
4 min read
